There is no phase III clinical trial of the vaccine over yet, but Pfizer and Modena recently said their vaccine is very effective. Believe me, I want to tell you that Chinese vaccines are also very effective. On November 19, Gao Fu, director of the Chinese Center for Disease Control and prevention and academician of the Chinese Academy of Sciences, said at the online academic conference new crown direct attack: cognition, prevention and control and prognosis jointly held by cellpress Cell Press and Beijing Science and Technology Commission.
On November 16, Zhong Nanshan, academician of the Chinese Academy of engineering, pointed out at the 2020 Guanzhou International Biological forum held in Guangzhou International Biological Island that foreign Pfizer vaccine can prevent 90% of the infection. In fact, the level of vaccine research and development in Guangdong and even China is similar, but the results of the first phase of the experiment can be published.
Sinopharma China biological new coronavirus inactivated vaccine
Chinas novel coronavirus pneumonia vaccine has been launched in three countries, including UAE, Bahrain, Egypt, Jordan, Peru, Argentina and other 10 countries. The group now has close to 60 thousand people, and more than 40 thousand of them have completed two days of blood sampling after 14 days of immunization, Liu Jingzhen said. Always good.
In terms of emergency use, we have now used it on nearly one million people, and we have not received any reports of serious adverse reactions, only individual patients have some mild symptoms. Liu Jingzhen said.
In addition, there has been no case of infection among construction workers, diplomats and overseas students from more than 150 countries in the world after vaccination. Liu Jingzhen cited an example. There were 99 employees in a multinational companys overseas offices, of which 81 were vaccinated. After the outbreak of the epidemic, 10 out of 18 people who had not been vaccinated were infected, while none of the vaccinated staff was infected.
If novel coronavirus pneumonia is novel coronavirus pneumonia, according to the global 6 billion person count, nearly 56 million people have been infected with the new crown pneumonia, according to the global infection rate, 56 thousand people will have a lot of new crown pneumonia after leaving the country, but no one infected with the number of people who have been vaccinated after the national vaccination, this data has very high reference value. Tao Lina, a vaccine expert, told the clients of China and New Zealand longitude and latitude.
Yang zhanqiu, a professor at the Institute of Virology, Wuhan University, pointed out that the effectiveness of the vaccine should be viewed objectively. He said that in terms of the new crown vaccine, efficacy and safety are two completely different concepts. The effectiveness refers to that after vaccination, the body will produce antibodies to avoid infection with the new coronavirus; while safety refers to whether the human body will have toxic reactions after vaccination, such as fever, diarrhea, redness and swelling of the inoculation site, and even organ damage in severe cases.
Yang zhanqiu pointed out that the effectiveness does not mean safety. The success of a new crown vaccine on the market depends on the effectiveness on the one hand and the safety on the other. Both are important indicators. In addition, Yang zhanqiu said that the current reported effective rate is not a fixed value, but will change with the change of infected population and sample size. The effectiveness of the new crown vaccine will also change due to gender, age and other factors.
When can new coronal vaccine hit? How about the price?
The new crown vaccine is coming. When can we have it? This is a topic of concern to many people.
In December, GUI Zhen, the chief disease control and prevention center of China Central Television, said that he could be vaccinated in November.
At present, some cities in China have been able to accept advance booking. Earlier, the Jiaxing Provincial Center for Disease Control and prevention of Zhejiang Province, the public Jiaxing disease control issued the official account of the new crown vaccination, said that the current new crown vaccine for emergency vaccination was unified by the provincial departments to Beijing Kexing Technology Co., Ltd., and was distributed to the designated vaccination units at a level by stage. The vaccine has not been officially registered on the market and has been approved for emergency vaccination according to law.
The above description shows that the emergency vaccination program of new crown vaccine is 2 doses, with an interval of 14-28 days, and the recommended interval is 28 days. The vaccination age is 18-59 years old. The price of the vaccine is 200 yuan / bottle, and the total cost of two doses is 400 yuan.
Zhang Wenhong, director of the infection department of Huashan Hospital Affiliated to Fudan University, recently said that only when the proportion of people vaccinated exceeds 60%. Novel coronavirus pneumonia will not be effectively prevented if the coverage is not achieved. The global restart will still face challenges.
To maintain a high level of vaccination rate, three points are needed: sufficient vaccine capacity, free vaccination provided by the government, and sufficient incentives or compulsory measures for the public to vaccinate.
How to choose vaccine?
Novel coronavirus pneumonia has been the first time since the outbreak of the new crown pneumonia outbreak. China has organized five technical routes: inactivated vaccine, recombinant protein vaccine, adenovirus vector vaccine, attenuated influenza virus vector vaccine and nucleic acid vaccine, and has carried out research and development in a standardized way. Up to now, five vaccines in China are conducting phase III clinical trials in UAE, Brazil, Pakistan, Peru and other countries, and several vaccines are stepping up the phase I and II clinical trials.
A novel coronavirus inactivated vaccine Kerr Lai Fu
Zhou Song, the general legal adviser of Sinopharm group, said in an interview with Zhongxin Jingwei reporter that the principle of inactivating the new crown vaccine is to use chemical reagents or physical methods to make the virus lose infectivity and replication, and retain the effective protein to stimulate the human immune response. In general, the preparation process of the two vaccines is simple and stable.
Both Moderna and Pfizer vaccines are mRNA vaccines (a new type of nucleic acid vaccine). Yang zhanqiu pointed out that the mRNA vaccine does not need a vector, but directly expresses the virus protective antigen gene in eukaryotic cells. The novel coronavirus pneumonia vaccine is relatively simple in comparison with the inactivated vaccine. The immunization is similar to natural infection, and can induce liquid immunity and cellular immunity, and has a cross protective effect on the same strain of mRNA. It has the effect of preventing new crown virus infection and the treatment of new crown pneumonia patients, but the preparation technology still needs to be improved. Yang zhanqiu said. Tao Lina pointed out that the mRNA vaccine can be rapidly replicated by nucleic acid characteristics, so the production cycle is short, and it is easy to mass produce. However, as an emerging technology, there is no vaccine based on this technology except the new crown vaccine. (Zhongxin Jingwei APP) source: Chen Hequn, editor in charge of China News Network_ NB12679
Both Moderna and Pfizer vaccines are mRNA vaccines (a new type of nucleic acid vaccine). Yang zhanqiu pointed out that the mRNA vaccine does not need a vector, but directly expresses the virus protective antigen gene in eukaryotic cells.
The novel coronavirus pneumonia vaccine is relatively simple in comparison with the inactivated vaccine. The immunization is similar to natural infection, and can induce liquid immunity and cellular immunity, and has a cross protective effect on the same strain of mRNA. It has the effect of preventing new crown virus infection and the treatment of new crown pneumonia patients, but the preparation technology still needs to be improved. Yang zhanqiu said.
Tao Lina pointed out that the mRNA vaccine can be rapidly replicated by nucleic acid characteristics, so the production cycle is short, and it is easy to mass produce. However, as an emerging technology, there is no vaccine based on this technology except the new crown vaccine. (Zhongxin Jingwei APP)